UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 08, 2024 |
ORTHOFIX MEDICAL INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
0-19961 |
98-1340767 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
3451 Plano Parkway |
|
|||
Lewisville, Texas |
|
75056 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (214) 937-2000 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Common stock, $0.10 par value per share |
|
OFIX |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 9, 2024, Orthofix Medical Inc. (the “Company”) issued a news release announcing, among other things, its preliminary unaudited net sales for the fiscal quarter and year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and attached hereto.
The information furnished in this Item 2.02, including the exhibit furnished herewith as Exhibit 99.1, will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 2.02 of this report.
Item 5.02 Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers.
Appointment of Massimo Calafiore as President and Chief Executive Officer, and as Director; Appointment of Julie Andrews as incoming Chief Financial Officer
On January 8, 2024, the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date. In addition, the Board expanded the size of the Board as of January 8, 2024 from eleven to twelve directors, and appointed Mr. Calafiore to fill the newly created seat.
On the same date, the Board appointed Julie Andrews as the Company’s Chief Financial Officer, effective as of January 15, 2024, when Ms. Andrews is expected to begin employment with the Company.
Mr. Calafiore, 52, served as the President and Chief Executive Officer of LimaCorporate S.p.A., a global orthopedic company focused on restoring motion through digital innovation and customized hardware, from September 2022 to January 2024, when it was acquired by Enovis Corporation. Previously, Mr. Calafiore served from September 2021 through August 2022 as Executive Vice President and Chief Commercial Officer of NuVasive, Inc., where he oversaw product marketing, commercial and commercial enablement functions, as well as NuVasive’s specialized orthopedics and clinical services. From October 2020 through August 2021, he served as NuVasive’s Executive Vice President, Global Business Units, where he was responsible for NuVasive’s product and services organization, including Spine, NuVasive Specialized Orthopedics (NSO) and NuVasive Clinical Services, and commercial enablement such as clinical professional development and global marketing. From 2017 until October 2020 he held various other leadership roles at NuVasive with increasing levels of responsibility, serving as Senior Vice President, Spine Business Unit, from January 2020 to October 2020, Senior Vice President, Global Implant Systems and General Manager of NSO, from February 2019 to December 2019, and Senior Vice President, General Manager of NSO from August 2017 to February 2019. Before his executive service at NuVasive, he spent more than 15 years supporting and leading the U.S. business for Waldemar Link, a leader in the orthopedics and medical device industry.
Ms. Andrews, 52, served as Chief Financial Officer of Smart Wires Technology, a global transmission grid technology company focused on enabling the transition to renewable energy, from August 2021 to April 2023. Between September 2019 and December 2020, she served as Senior Vice President, Global Finance of Wright Medical Group, where she led a 170-person finance team. She served from May 2012 to August 2019 as Wright Medical’s Vice President of Finance and Chief Accounting Officer, where she held responsibility for corporate FP&A, business-unit FP&A, operations finance and accounting functions of the business on a global basis. Prior to this, she spent 14 years in roles of increasing responsibility at Medtronic Inc., including as Vice President of Finance for the Spine and Biologics division, where she provided oversight of all FP&A and accounting functions. Early in her career, she served as a Senior Financial Analyst for Thomas & Betts and as an auditor for Thomas Havey, LLC. Currently, she serves on the board of RxSight, Inc., an ophthalmic medical device company. She received a Bachelor of Science in Accounting from Indiana University. She also participated in advanced leader and director development programs at both Medtronic and Wharton School of Business.
Change in Control and Severance Agreement with Mr. Calafiore
In connection with his entering into employment on January 8, 2024, the Company and Mr. Calafiore entered into a Change in Control and Severance Agreement, which agreement was approved by the Compensation and Talent Development Committee of the Board. The Change in Control and Severance Agreement is on terms substantially similar to the form of CEO-level agreement previously approved by the committee in June 2023.
Under the Change in Control and Severance Agreement, Mr. Calafiore would be eligible to receive the following severance payments and benefits upon termination of his employment (i) for death or disability, (ii) by the Company without “Cause” (as defined in the agreement) or (iii) by him for “Good Reason” (as defined in the agreement):
The Company’s obligation to pay or provide the cash severance and COBRA reimbursement benefits described above are conditioned upon him signing a release of claims in favor of the Company and its affiliates by a specified date following separation from the Company. The agreement also incorporates by reference, among other things, covenants of the executive with respect to confidentiality, assignment of intellectual property, non-competition and non-solicitation of employees. The term of the agreement continues in effect until the earlier of (i) the parties’ satisfaction of their respective obligations or (ii) the execution of a written agreement between the Company and Mr. Calafiore terminating the agreement.
The foregoing descriptions do not purport to be complete and are qualified in their entirety by reference to the full text of the agreement, which is filed herewith as Exhibits 10.1 and incorporated herein by reference.
Inducement Plan for Mr. Calafiore
As an inducement to entering into employment with the Company, Mr. Calafiore was granted, as of January 8, 2024, (i) sign-on equity incentive awards with a grant date fair value of $3,500,000, and (ii) 2024 annual equity incentive awards with a grant date fair value of $4,000,000 (collectively, the “CEO Inducement Awards”). The CEO Inducement Awards, were granted pursuant to NASDAQ Marketplace Rule 5635(c)(4), and were allocated (i) 50% as performance-based vesting restricted stock units determined at the end of a 3-year performance period based on the Company’s total stockholder return relative to an industry peer group index during such period, (ii) 25% as stock options that vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company’s common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company’s common stock on the grant date, and (iii) 25% as time-based restricted stock units vesting in equal tranches over three years.
The awards were granted pursuant to a standalone inducement plan, the Orthofix Medical Inc. 2024 CEO Inducement Plan (the “2024 CEO Inducement Plan”), which plan was approved by the Board as of January 8, 2024. A copy of the 2024 CEO Inducement Plan has been filed as Exhibit 4.2, and copies of the forms of award agreements have been filed as Exhibits 4.3, 4.4 and 4.5, respectively, to the Company’s Registration Statement on Form S-8 (Registration No. 333-276433) filed with the Securities and Exchange Commission on January 8, 2024. The foregoing descriptions of the 2024 CEO Inducement Plan and the related forms of award agreements thereunder do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, which are incorporated herein by reference.
Offer Letter with Ms. Andrews
In connection with her appointment as the Company’s incoming Chief Financial Officer, the Company and Ms. Andrews entered into a letter agreement setting forth certain terms of her employment (the “Offer Letter Agreement”). Under the terms of the Offer Letter Agreement, Ms. Andrews will receive an annual base salary of $475,000 per year, and a target bonus opportunity under the Company’s annual incentive program of 70% of such base salary. As an inducement to entering into employment with the Company, she will receive sign-on equity incentive awards with a grant date fair value of $1,800,000 (collectively, the “CFO Inducement Awards”). The CFO Inducement Awards, which will be granted effective as of her first date of employment with the Company pursuant to NASDAQ Marketplace Rule 5635(c)(4), will be allocated (i) 50% as performance-based vesting restricted stock units determined at the end of a 3-year performance period based on the Company’s total stockholder return relative to an industry peer group index during such period, (ii) 25% as stock options that vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company’s common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company’s common stock on the grant date, and (iii) 25% as time-based restricted stock units vesting in equal tranches over three years. Ms. Andrews will be provided an executive level after-tax relocation payment of $225,000 to support establishing residency in the Lewisville, Texas area.
In connection with her employment, Ms. Andrews will be provided the opportunity to enter into the Company’s standard CFO-level change in control and severance agreement and indemnification agreement. The foregoing descriptions do not purport to be complete and are qualified in their entirety by reference to the full text of the Offer Letter Agreement, which is filed herewith as Exhibit 10.2 and incorporated herein by reference.
Departure of Kevin Kenny
On January 7, 2024, the Company and Kevin Kenny agreed that Mr. Kenny would depart as an employee and officer as of January 8, 2024. Under the agreement between the parties, Mr. Kenny will remain available to provide consulting services to the Company for up to twelve months, and will be paid $500 per hour for any consulting services provided. Mr. Kenny’s departure will be treated under his change in control and severance agreement with the Company as a termination of employment without Cause during a CiC Period, and Mr. Kenny will be entitled to receive the payments and benefits provided for thereunder, subject to compliance with the terms and conditions of such agreement. In addition, the Company has agreed to reimburse Mr. Kenny for approximately $21,000 in apartment lease costs in the Dallas, Texas region on an after-tax basis, and to extend his stock option exercise period for an additional twelve months from the period provided for in the change in control and severance agreement.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
10.1 |
|
10.2 |
Letter agreement, dated as of January 4, 2024, between Orthofix Medical Inc. and Julie Andrews |
99.1 |
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Orthofix Medical Inc. |
|
||
By: |
|
/s/ Geoffrey Gillespie |
|
|
|
Geoffrey Gillespie Interim Chief Financial Officer |
|
Date: January 9, 2024
ORTHOFIX MEDICAL INC.
CHANGE IN CONTROL AND SEVERANCE AGREEMENT
This AGREEMENT (the “Agreement”) is made and entered into as of January 8, 2024 (the “Effective Date”), by and between Orthofix Medical Inc., a Delaware corporation (together with its direct and indirect subsidiaries, the “Company”), and Massimo Calafiore (the “Executive”).
RECITALS
WHEREAS, the Executive is expected to make significant contributions to the profitability, growth and financial strength of the Company;
WHEREAS, the Company believes that it is important to provide the Executive with severance benefits upon certain terminations of employment to provide the Executive with enhanced financial security and incentive and encouragement to remain with the Company;
WHEREAS, the Company recognizes that the possibility of a Change in Control (as hereinafter defined) and the uncertainty that it would cause could result in the departure or distraction of the Executive, to the detriment of the Company and its stockholders; and
WHEREAS, the Company desires to encourage the continued employment of the Executive by the Company and wants assurance that it shall have the continued dedication, loyalty and service of, and the availability of objective advice and counsel from, the Executive notwithstanding the possibility, threat or occurrence of a Change in Control.
NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 1
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 2
MACROBUTTON DocID \\4130-4759-9438 v1
Notwithstanding this definition of “Change in Control,” the Board, in its sole discretion, may determine that a Change in Control has occurred for purposes of this Agreement, even if the events giving rise to such Change in Control are not expressly described in the above definition.
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 3
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 4
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 5
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 6
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 7
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 8
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 9
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 10
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 11
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 12
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 13
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 14
MACROBUTTON DocID \\4130-4759-9438 v1
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 15
MACROBUTTON DocID \\4130-4759-9438 v1
IN WITNESS WHEREOF, each of the undersigned has executed this Agreement as of the date first above written.
ORTHOFIX MEDICAL INC.
By: /s/ Michael E. Paolucci Michael E. Paolucci |
EXECUTIVE
/s/ Massimo Calafiore Massimo Calafiore |
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 16
MACROBUTTON DocID \\4130-4759-9438 v1
EXHIBIT A
Release
You, for yourself, your spouse and your agents, successors, heirs, executors, administrators and assigns, hereby irrevocably and unconditionally forever release and discharge Orthofix Medical Inc., a Delaware corporation, and its direct and indirect subsidiaries (all such entities, collectively, the “Company”), its parents, divisions and affiliates and its and their current and former owners, directors, officers, stockholders, insurers, benefit plans, representatives, agents and employees, and each of their predecessors, successors, and assigns (collectively, the “Releasees”), from any and all actual or potential claims or liabilities of any kind or nature, including, but not limited to, any claims arising out of or related to your employment and separation from employment with the Company and any services that you provided to the Company; any claims for salary, commissions, bonuses, other severance pay, vacation pay, allowances or other compensation, or for any benefits under the Employee Retirement Income Security Act of 1974 (“ERISA”) (except for vested ERISA benefits); any claims for discrimination, harassment or retaliation of any kind or based upon any legally protected classification or activity; any claims under Title VII of the Civil Rights Acts of 1964, the Civil Rights Act of 1866 and 1964, as amended, 42 U.S.C. § 1981, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Americans with Disabilities Act, 42 U.S.C. §1981, 42 U.S.C. § 1983, the Family Medical Leave Act and any similar state law, the Fair Credit Reporting Act and any similar state law, the Fair Credit Reporting Act, 15 U.S.C. § 1681, et seq., the Worker Adjustment and Retraining Notification Act, 29 U.S.C. § 2101, et seq., the Equal Pay Act and any similar state law, as well as any amendments to any such laws; any claims for any violation of any federal or state constitutions or executive orders; any claims for wrongful or constructive discharge, violation of public policy, breach of contract or promise (oral, written, express or implied), personal injury not covered by workers’ compensation benefits, misrepresentation, negligence, fraud, estoppel, defamation, infliction of emotional distress, contribution and any claims under any other federal, state or local law, including those not specifically listed in this Release, that you, your heirs, executors, administrators, successors, and assigns now have, ever had or may hereafter have, whether known or unknown, suspected or unsuspected, up to and including the date of your execution of this Release.
For the purpose of implementing a full and complete release and discharge of the Releasees as set forth above, you acknowledge that this Release is intended to include in its effect, without limitation, all claims known or unknown that you have or may have against the Releasees which arise out of or relate to your employment, including but not limited to compensation, performance or termination of employment with the Company, except for, and notwithstanding anything in this Release to the contrary, claims which cannot be released solely by private agreement. This Release also excludes any claims relating to any right you may have to (a) payments and benefits pursuant to Sections 3 or 4 of the Change in Control and Severance Agreement, entered into as of January 8, 2024, by and between the Company and me, (b) vesting, exercise, settlement, and/or payment of your outstanding equity awards from the Company, in accordance with the terms and conditions of the applicable equity plan document and/or award agreement, (c) workers’ compensation benefits, and (d) any rights you may have to indemnification or directors’ and officers’ liability insurance under the Company’s articles of association, certificates of incorporation or bylaws, insurance policies, any indemnification agreement to which you are a party or beneficiary or applicable law, as a result of having served as an officer, director or employee of the Company or any of its affiliates.
You affirm, by signing this Release, that you have not suffered any unreported injury or illness arising from your employment. You further agree that while this Release does not preclude you from filing a charge with the National Labor Relations Board (“NLRB”), the Equal Employment Opportunity
Change in Control and Severance Agreement — Massimo Calafiore
Effective Date: January 8, 2024 Page 17
MACROBUTTON DocID \\4130-4759-9438 v1
Commission (“EEOC”) or a similar federal, state or local agency, or from participating in any investigation or proceeding with them, you do waive your right to personally recover monies or reinstatement as a result of any complaint or charge filed against the Company with the NLRB, EEOC, or any federal, state or local court or agency with respect to any claim released by you in this Release.
You understand that the claims released in this Release do not include claims by you for: (1) unemployment insurance; (2) worker’s compensation benefits; (3) state disability compensation; (4) previously vested benefits under any Company-sponsored benefits plan; and (5) any other rights that cannot by law be released by private agreement.
The Company agrees that in exchange for your continued commitment to Section 9(b) of the agreement to which this Release is attached, that, within seven (7) days of the effective date of this Release, it will provide a written instruction to its then-present Board of Directors not to purposefully make or publish, directly or indirectly, any public statement disparaging you. Notwithstanding the foregoing, it is understood that the instruction shall not forbid any director from (i) discussing or disclosing information about unlawful, unethical, or improper acts in the workplace, such as harassment or discrimination or any other conduct that such director has reason to believe is unlawful, unethical, or improper, (ii) cooperating in any investigation or providing testimony in legal proceedings (whether administrative or judicial), (iii) making truthful statements in connection with the Company’s enforcement of its rights against Executive, whether under contract, statutory, or common law, (iv) responding accurately and fully to any question, inquiry or request for information when required by legal process, or in connection with any of the Company’s communications with government agencies or other regulatory bodies; (v) making statements in connection with the Company’s filing of disclosures with the Securities and Exchange Commission or any other governmental authority; or (vi) engaging in internal Company discussions regarding you.
You acknowledge:
Change in Control and Severance Agreement— Massimo Calafiore
Effective Date: January 8, 2024 Page 18
MACROBUTTON DocID \\4130-4759-9438 v1
PLEASE READ CAREFULLY. THIS RELEASE INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.
ACKNOWLEDGED AND AGREED
____________________________________________________________
Massimo Calafiore Date
Change in Control and Severance Agreement— Massimo Calafiore
Effective Date: January 8, 2024 Page 19
MACROBUTTON DocID \\4130-4759-9438 v1
January 4, 2024
Julie Andrews
25 Lancaster Drive
Arlington, TN 38002
Dear Julie:
It gives me great pleasure to present this offer of employment with Orthofix Medical, Inc. (with its subsidiaries and affiliates, “Orthofix”).
Position: The position we are offering you is that of Chief Financial Officer.
Start Date: Your starting date will be on or before January 15, 2024.
Base Salary: Your base salary will be $475,000 per year (the “Base Salary”), less applicable deductions and tax withholdings.
Annual Bonus: Subject to Orthofix policies and satisfaction of applicable performance criteria, you will be eligible to participate in the annual bonus program, with a target bonus opportunity of 70% of your Base Salary. Your 2024 annual bonus will not be pro-rated based on your start date. The annual bonus, if payable, will be paid at the same time that such bonuses are paid to other executives, and will be designed to either be exempt from or comply with Internal Revenue Code Section 409A, as determined by the Compensation and Talent Development Committee of Orthofix’s Board of Directors (the “C&TD Committee”) upon establishment each year.
Sign-On Equity Award ($1,800,000): As an inducement to and incentive for accepting this position, you will receive a grant, effective as of your start date, of (i) performance-based restricted stock units (“P-RSUs”), valued at $900,000 (based on the closing price of Orthofix common stock on the grant date, subject to rounding to the nearest whole unit), (ii) Stock Options to purchase shares of Orthofix common stock, valued at $450,000 (based on the Black-Scholes value of Orthofix common stock on the grant date, subject to rounding to the nearest whole option share), and (iii) restricted stock units (“RSUs”) with respect to shares of Orthofix common stock, valued at $450,000 (based on the closing price of Orthofix common stock on the grant date, subject to rounding to the nearest whole unit). All such awards will be subject to continued employment through applicable vesting dates (subject to any applicable acceleration rights).
P-RSUs vesting determined at the end of the 3-year performance period based on Orthofix total shareholder return relative to an industry peer group index, which vesting may be anywhere from 0% to 200% of the target P-RSU amount based on the achievement of the performance goals. If during the term of the Stock Options the average closing price of the Company’s common stock over a one-month calendar period has been equal to or greater than 150% of the closing price of the Company’s common stock on the grant date (the “Sign-On Option Exercise Condition”), the Stock Options will vest upon the later of (i) the date on which the Sign-On Option Exercise Condition is achieved and (ii) the date on which you meet the applicable service-based conditions. The applicable service-based conditions will be met with respect to 1/3 of the Stock Options on the one-year anniversary of the Stock Options’ grant date and with respect to 1/12 of the Stock Options as of the end of each 3-month period during the two years following such one-year anniversary of the grant date. RSUs will vest in annual 33-1/3% installments, with the first tranche vesting on the one-year anniversary of the RSUs’ grant date and the second and third tranches vesting on the two and three year anniversaries of the grant date, respectively.
Orthofix Medical Inc. | 3451 Plano Parkway | Lewisville, TX 75056 | 214.937.2000
www.orthofix.com
MACROBUTTON DocID \\4127-9581-0126 v1
Upon any future Change in Control (as defined under the Change in Control and Severance Agreement), (i) the performance goals for the P-RSUs will be deemed achieved at the greater of 100% of target or actual achievement through the Change in Control closing date and (ii) the Sign-On Option Exercise Condition will be deemed achieved. The sign-on equity awards will be subject to the terms and conditions of applicable award agreements.
Benefits: Orthofix will offer you medical, dental, and vision insurance, effective the first of the month after your first 30 days of employment. You will also be eligible to participate in the Orthofix 401(k) retirement plan as of the first of the month after your first 30 days of employment. This plan currently provides an employer match of 100% for the first 2% contribution and 50% for the next 4% contribution. A more detailed explanation of these benefits and other benefits will be provided to you under separate cover. Orthofix defers to the provisions of its employee benefits plans, which plans shall govern to the extent of any conflict and which plans may be changed unilaterally by Orthofix.
Relocation Assistance: Your position will be based in Orthofix’s Lewisville, TX offices and as such, Orthofix will provide you with a relocation payment, in an amount such that the estimated after-tax portion (calculated to assume that you are subject to U.S. federal and Texas state income tax, but not subject to income tax in any other jurisdiction) of such amount will be equal to $225,000, such payment to be used for expenses to support establishing residency in the Lewisville, TX area on or before July 1, 2024. The relocation payment will be made in two installments, the first within 30 days of your starting date and second within 30 days of your relocation to Texas.
Third-Party Confidentiality/Non-Compete Obligations: Orthofix recognizes that, while you were employed with your prior employers, you may have been exposed to confidential, proprietary, and/or trade secret information (“Third-Party Confidential Information”). Moreover, Orthofix recognizes that you have a legal duty and may have a contractual duty not to use or disclose Third-Party Confidential Information outside of your employment with your former employers. Orthofix also recognizes that you may owe your former employers a contractual duty not to solicit certain customers (“Restricted Customers”). Orthofix has no intention of obtaining any Third-Party Confidential Information in any form. In fact, Orthofix’s expectation is that you will abide by, and comply fully with, the terms of any agreements you may have with respect to such information. By signing below, you represent and warrant that you have complied, and will comply, with any such obligations, including, but not limited to, all confidentiality, non-solicitation, non-competition, and post-employment disclosure obligations. You further represent and warrant that you have not misappropriated any Third-Party Confidential Information and, to the extent you may have access to such information, you will not disclose or use it for any purpose contrary to the terms of any agreements you may have with respect to such information, or to benefit Orthofix in any way.
Orthofix also wishes to ensure that you are not placed in a position which might require you to solicit Restricted Customers or cause the disclosure or use of Third-Party Confidential Information, either intentionally or inadvertently. If you are ever involved in any job situation which could require you to solicit Restricted Customers or cause you to use or disclose any Third-Party Confidential Information, you agree to immediately notify Orthofix’s Chief Legal Officer and advise Orthofix’s Chief Legal Officer of your concerns. In the event it is determined that a risk of improper solicitation, disclosure, or use does exist, Orthofix will take appropriate measures.
Employment-At-Will: You understand and acknowledge that, if you become employed by Orthofix, you will be an “at-will” employee at all times during your employment. As an at-will employee, both Orthofix and you will have the right to terminate your employment at any time, with or without cause, and with or without notice. At-will employment also means that your job duties, title, compensation, and benefits, as well as the company personnel policies and other procedures, may be changed or terminated at the sole discretion of Orthofix at any time. Please note that, while this offer letter summarizes your anticipated terms and conditions of employment with Orthofix, they may change, and it is not an employment contract.
Other Agreements: Under separate cover, you will receive a Change in Control and Severance Agreement, a Dispute Resolution Agreement, a Confidentiality and Invention Assignment Agreement, and an
Orthofix Medical Inc. | 3451 Plano Parkway | Lewisville, TX 75056 | 214.937.2000
www.orthofix.com
MACROBUTTON DocID \\4127-9581-0126 v1
Indemnification Agreement (the “Other Agreements”), which will become effective as of your first day of employment. Any expense reimbursements or in kind benefits under this offer letter that constitute deferred compensation within the meaning of Section 409A of the Internal Revenue Code shall be made or provided in accordance with the requirements of Section 409A, including, without limitation, that: (i) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was incurred; and (iii) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.
Acceptance: Your signature at the end of this offer letter constitutes an acceptance of this offer and confirms that no promises, representations, or agreements that are inconsistent with any of the terms of this offer letter have been made to or with you by anyone at Orthofix. Upon acceptance of this Offer Letter the offer and the terms set forth herein are binding and irrevocable by Orthofix until and following the effectiveness of the Change of Control and Severance Agreement.
Julie, we look forward to working with you. Your experience, background and leadership will be a significant asset to Orthofix.
Sincerely,
/s/ Catherine M. Burzik
Catherine M. Burzik
Chair of the Board and Interim President and Chief Executive Officer
ACKNOWLEDGED, ACCEPTED, AND AGREED:
/s/ Julie Andrews Date: January 4, 2024
Julie Andrews
Orthofix Medical Inc. | 3451 Plano Parkway | Lewisville, TX 75056 | 214.937.2000
www.orthofix.com
MACROBUTTON DocID \\4127-9581-0126 v1
Exhibit 99.1
Orthofix Medical Inc. Announces Preliminary 2023 Fourth Quarter and Full-Year Net Sales Results
LEWISVILLE, Texas — January 9, 2024 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced preliminary unaudited fourth quarter 2023 net sales of approximately $200.3 million, an increase of 63.8% on a reported basis and 62.8% on a constant currency basis versus fourth quarter 2022. For the full year 2023, preliminary unaudited net sales were approximately $746.5 million, an increase of 62.0% on a reported basis and 61.5% on a constant currency basis.
"We are very pleased with our results for the fourth quarter of 2023 and believe the strength and stability Orthofix exhibited through the end of the year will continue into 2024," said Catherine Burzik, Chair of the Board of Directors and former Interim CEO of Orthofix. "Our preliminary revenue numbers reflect heightened performance and increased momentum across all business segments; BGT reported another sequential quarter of double-digit growth, and the Orthopedics segment finished 2023 having grown revenue by 7% over the prior year. Enabling Technologies set a revenue record in the fourth quarter, and within U.S. Spine, our commercial teams were able to leverage unique opportunities in the market to sign agreements with multiple high-value distributors. I remain proud of the unwavering commitment of the Orthofix team to continuously realize merger synergies and drive value creation for the Company and its shareholders."
Financial Results Overview
The following provides net sales by major product category by reporting segment on a reporting basis:
|
|
Three Months Ended December 31, |
|
|||||||||||||
(Unaudited, U.S. Dollars, in millions) |
|
2023 |
|
|
2022 |
|
|
Change |
|
|
Constant |
|
||||
Bone Growth Therapies |
|
$ |
58.8 |
|
|
$ |
51.0 |
|
|
|
15.3 |
% |
|
|
15.3 |
% |
Spinal Implants, Biologics and Enabling Technologies |
|
|
110.8 |
|
|
|
42.5 |
|
|
|
160.5 |
% |
|
|
160.3 |
% |
Global Spine |
|
|
169.6 |
|
|
|
93.6 |
|
|
|
81.3 |
% |
|
|
81.2 |
% |
Global Orthopedics |
|
|
30.6 |
|
|
|
28.7 |
|
|
|
6.8 |
% |
|
|
2.7 |
% |
Net sales |
|
$ |
200.3 |
|
|
$ |
122.2 |
|
|
|
63.8 |
% |
|
|
62.8 |
% |
Further, the following tables provides net sales by major product category by reporting segment on a pro forma basis:
|
|
Three Months Ended December 31, |
|
|||||||||||||
(Unaudited, U.S. Dollars, in millions) |
|
2023 |
|
|
2022 Pro Forma |
|
|
Change |
|
|
Constant |
|
||||
Bone Growth Therapies |
|
$ |
58.8 |
|
|
$ |
51.0 |
|
|
|
15.3 |
% |
|
|
15.3 |
% |
U.S. Spinal Implants, Biologics and Enabling Technologies |
|
|
100.6 |
|
|
|
96.4 |
|
|
|
4.4 |
% |
|
|
4.4 |
% |
International Spinal Implants, Biologics and Enabling Technologies |
|
|
10.2 |
|
|
|
10.3 |
|
|
|
(0.8 |
%) |
|
|
(15.4 |
%) |
Total Spinal Implants, Biologics and Enabling Technologies |
|
|
110.8 |
|
|
|
106.7 |
|
|
|
3.9 |
% |
|
|
2.5 |
% |
Global Spine |
|
|
169.6 |
|
|
|
157.7 |
|
|
|
7.6 |
% |
|
|
6.6 |
% |
Global Orthopedics |
|
|
30.6 |
|
|
|
28.7 |
|
|
|
6.8 |
% |
|
|
2.7 |
% |
Net sales |
|
$ |
200.3 |
|
|
$ |
186.4 |
|
|
|
7.5 |
% |
|
|
6.0 |
% |
1
Full Year Net Sales Results
The following provides net sales by major product category by reporting segment on a reporting basis:
|
|
Year Ended December 31, |
|
|||||||||||||
(Unaudited, U.S. Dollars, in millions) |
|
2023 |
|
|
2022 |
|
|
Change |
|
|
Constant |
|
||||
Bone Growth Therapies |
|
$ |
212.5 |
|
|
$ |
187.2 |
|
|
|
13.5 |
% |
|
|
13.5 |
% |
Spinal Implants, Biologics and Enabling Technologies |
|
|
418.6 |
|
|
|
165.9 |
|
|
|
152.3 |
% |
|
|
152.3 |
% |
Global Spine |
|
|
631.2 |
|
|
|
353.2 |
|
|
|
78.7 |
% |
|
|
78.7 |
% |
Global Orthopedics |
|
|
115.3 |
|
|
|
107.5 |
|
|
|
7.2 |
% |
|
|
5.2 |
% |
Net sales |
|
$ |
746.5 |
|
|
$ |
460.7 |
|
|
|
62.0 |
% |
|
|
61.5 |
% |
Further, the following tables provides net sales by major product category by reporting segment on a pro forma basis:
|
|
Year Ended December 31, |
|
|||||||||||||
(Unaudited, U.S. Dollars, in millions) |
|
2023 |
|
|
2022 Pro Forma |
|
|
Change |
|
|
Constant |
|
||||
Bone Growth Therapies |
|
$ |
212.5 |
|
|
$ |
187.2 |
|
|
|
13.5 |
% |
|
|
13.5 |
% |
U.S. Spinal Implants, Biologics and Enabling Technologies |
|
|
379.4 |
|
|
|
352.5 |
|
|
|
7.6 |
% |
|
|
7.7 |
% |
International Spinal Implants, Biologics and Enabling Technologies |
|
|
39.2 |
|
|
|
53.6 |
|
|
|
(26.8 |
%) |
|
|
(29.6 |
%) |
Total Spinal Implants, Biologics and Enabling Technologies** |
|
|
418.6 |
|
|
|
406.0 |
|
|
|
3.1 |
% |
|
|
2.7 |
% |
Global Spine |
|
|
631.2 |
|
|
|
593.3 |
|
|
|
6.4 |
% |
|
|
6.1 |
% |
Global Orthopedics |
|
|
115.3 |
|
|
|
107.5 |
|
|
|
7.2 |
% |
|
|
5.2 |
% |
Net sales *** |
|
$ |
746.5 |
|
|
$ |
700.8 |
|
|
|
6.5 |
% |
|
|
6.0 |
% |
** Pro forma net sales for 2022 for Spinal Implants, Biologics, and Enabling Technologies include the impact of final Spinal Implant stocking orders to European distributors prior to SeaSpine's exit from that market. Excluding the impact of these transactions, net sales growth for this product category was 6.2% on a pro forma reported basis and 5.8% on a pro forma constant currency basis.
*** Pro forma net sales for 2022 include the impact of final Spinal Implant stocking orders to European distributors prior to SeaSpine's exit from that market. Excluding the impact of these transactions, net sales growth was 8.4% on a pro forma reported basis and 7.8% on a pro forma constant currency basis.
Inducement Grants to Massimo Calafiore under Nasdaq Listing Rule 5635(c)(4)
On January 8, 2024, Massimo Calafiore began service as the Company’s President and Chief Executive Officer. Mr. Calafiore joins the Company after previously having served as Chief Executive Officer of LimaCorporate S.p.A., a global orthopedics company. As an inducement to entering into employment with the Company, Mr. Calafiore was granted (i) performance-based vesting restricted stock units that settle 282,167 shares of common stock at target achievement, (ii) time-based vesting restricted stock units that settle into 141,084 shares of common stock, and (iii) stock options to purchase 329,005 shares of common stock. The performance-based vesting restricted stock units vest at the end of a 3-year performance period based on the Company’s total stockholder return relative to an industry peer group index during such period, while the time-based vesting restricted stock units vest in equal tranches over three years. The stock options vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company’s common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company’s common stock on the grant date. The grants, which were approved by the Compensation & Talent Development Committee of the Company’s Board of Directors, were made effective as of January 8, 2024 under a standalone inducement plan
2
approved pursuant to Nasdaq Marketplace Rule 5635(c)(4), but on terms substantially the same as grants made in the ordinary course under the Company’s 2012 Long Term Incentive Plan, as amended.
About Orthofix
Orthofix and SeaSpine merged in January 2023 to form a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions and a leading surgical navigation system. Its products are distributed in approximately 68 countries worldwide.
The Company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France, and São Paulo, Brazil. To learn more, visit Orthofix.com.
Constant Currency
Constant currency is a non-GAAP measure, which is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.
Usefulness and Limitations of Non-GAAP Financial Measures
Management uses non-GAAP measures to evaluate performance period-over-period, to analyze the underlying trends in our business, to assess performance relative to competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP measures to further its understanding of the performance of our business units.
Material Limitations Associated with the Use of Non-GAAP Financial Measures
The non-GAAP measures used in this news release may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures.
Compensation for Limitations Associated with Use of Non-GAAP Financial Measures
We compensate for the limitations of our non-GAAP financial measures by relying upon GAAP results to gain a complete picture of our performance. The GAAP results provide the ability to understand our performance based on a defined set of criteria. The non-GAAP measures reflect the underlying operating results of our businesses, which we believe is an important measure of our overall performance.
Usefulness of Non-GAAP Financial Measures to Investors
Management believes it is important to provide investors with the same non-GAAP metrics it uses to supplement information regarding the performance and underlying trends of our business operations in order to facilitate comparisons to our historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. Forward-looking statements in this communication include the Company's expectations regarding net sales and adjusted EBITDA for the year ended December 31, 2023. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”), and in Part
3
II, Item 1A under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to recruit and retain management and key personnel, (vii) global economic instability and potential supply chain disruption caused by Russia’s invasion of Ukraine and resulting sanctions, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.
This list of risks, uncertainties, and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law.
Company Contact |
Louisa Smith, Gilmartin Group |
ir@orthofix.com |
Source
Orthofix Medical Inc.
4